SCHEMBL343020

SCHEMBL343020

CC(C)(C)OC(=O)N1CC1Cc1cc(F)c(F)cc1F

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.51
NR1H2 P55055 4/20 0.39
NR1H3 Q13133 3/20 0.39
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
ECE1 P42892 1/20 0.37
KCNH2 Q12809 1/20 0.36
HSD11B1 P28845 1/20 0.36
USP30 Q70CQ3 1/20 0.36
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
CYP2D6 P10635 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
TACR1 P25103 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL343021 1.00 DPP4 (0.51) DPP4NR1H2NR1H3CYP1A2POLB
SCHEMBL542233 0.86 DPP4 (0.39) DPP4CYP3A4ECE1KCNH2CYP2D6
SCHEMBL343752 0.81 ABCB1 (0.44) DPP4CYP3A4KCNH2CYP2D6DPP8
SCHEMBL343753 0.81 ABCB1 (0.44) DPP4CYP3A4KCNH2CYP2D6DPP8
SCHEMBL5407129 0.80 ECE1 (0.47) DPP4NR1H2NR1H3CYP1A2POLB
SCHEMBL344727 0.79 DPP4 (0.38) DPP4CYP3A4KCNH2CYP2D6DPP8
SCHEMBL5404207 0.79 ECE1 (0.47) DPP4NR1H2NR1H3CYP1A2POLB
SCHEMBL28070441 0.78 DPP4 (0.38) DPP4CYP3A4KCNH2CYP2D6DPP8
SCHEMBL27963865 0.78 DPP4 (0.38) DPP4CYP3A4KCNH2CYP2D6DPP8
SCHEMBL5405247 0.76 ECE1 (0.64) DPP4NR1H2NR1H3CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103922971-B For the preparation of improving one's methods of the intermediate of dipeptidyl peptidase-iv inhibitor DONG-A ST CO., LTD. (KR) 2016-05-11 CN disclosed
US-9249109-B2 Method for preparing dipeptidyl peptidase-IV inhibitor and intermediate DONG-A PHARMACEUTICAL CO., LTD. (KR) 2016-02-02 US disclosed
US-20150025241-A1 METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DONG-A PHARMACEUTICAL. CO., LTD (KR) 2015-01-22 US disclosed
EP-2415753-B1 METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DONG A PHARM CO LTD (KR) 2014-08-27 EP disclosed
CN-102378751-B Improved process for preparing dipeptidyl peptidase-IV inhibitors and intermediates DONG A PHARM CO LTD 2014-08-20 CN disclosed
CN-103922971-A Improved Method For Preparing Intermediate Of Dipeptidyl Peptidase-iv Inhibitor DONG A PHARM CO LTD 2014-07-16 CN disclosed
EP-2669265-A2 Improved method for preparing dipeptidyl peptidase-IV inhibitor and intermediate Dong-A Pharmaceutical Co., Ltd. (KR) 2013-12-04 EP disclosed
EP-2415753-A2 IMPROVED METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE Dong-A Pharmaceutical Co., Ltd. (KR) 2012-02-08 EP disclosed
US-20120016125-A1 METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DONG-A PHARMACEUTICAL. CO., LTD (KR) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025241-A1 METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DPP4, DPP3, DPP7 DPP4 1/4885NR1H2 4532/4885NR1H3 4293/4885
US-20120016125-A1 METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DPP4, DPP3, DPP7 DPP4 1/4885NR1H2 4532/4885NR1H3 4293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.